Kyri van Hoose

Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.

TEGA Therapeutics, Inc. produces recombinant heparan sulfate and enzyme replacement therapies for lysosomal storage diseases. The company is based in San Diego, CA. Glass, Jeffrey D. Esko. TEGA Therapeutics was founded by Yitzhak Tor, Timothy Scott, Charles A. Timothy Scott has been the CEO since incorporation.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Avelas Biosciences, Inc. develops integrated suite of therapeutic and imaging agents for treatment of cancer. It develops AVB-620, an intravenously administered in vivo fluorescent protease activatable peptide that detects, marks, and diagnoses cancer. The company was founded by Yon Chien Tsien, Quyen T. Nguyen and Michael A. Whitney in 2008 and is headquartered in La Jolla, CA.